Press Release: Emerging data from CLL10 presented at ASH suggests Levact® (bendamustine) and rituximab as new treatment option for fit elderly CLL patients
New interim analysis study findings presented for the first time today at the 55th American Society of Hematology (ASH) Annual Meeting in New Orleans suggest bendamustine and rituximab… read more.